- Three poster presentations showing
- the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.
- the reduction of the FastTM score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.
- the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibranor.
Daix (France), Long Island City (New York, United States), June 9, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that three abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2022 hosted by the European Association for the Study of the Liver (EASL) on June 22-26, 2022 in London, UK.
The first abstract focuses on the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with NASH showing that they are independent of weight change. Based on the results of Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH, the authors of the abstract analysed markers of cardiometabolic health in relation with the weight variation observed in patients…
